Cumberland Partners’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.63M Buy
+11,500
New +$1.85M 0.11% 97
2024
Q2
– Sell
-3,000
Closed -$414K – 196
2024
Q1
$414K Buy
+3,000
New +$410K 0.03% 173

Other funds holding NBIX

Cumberland Partners's NBIX Position: Q3 2026 in Review

Cumberland Partners opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 11,500 shares worth $1.63M. The stake represents 0.11% of the portfolio and ranks #97 among its holdings. This is a return to the name: Cumberland Partners previously reported a position in NBIX as recently as Q1 2024.

Cumberland Partners first reported a position in NBIX in Q1 2024 and has held it in 2 quarters since. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Cumberland Partners held 11,500 shares of Neurocrine Biosciences worth $1.63M as of Q3 2026.
  • Neurocrine Biosciences was a new Cumberland Partners position in Q3 2026.
  • Neurocrine Biosciences made up 0.11% of Cumberland Partners's portfolio in Q3 2026, its #97 holding.
  • Cumberland Partners first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 2 quarters since.
  • 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Cumberland Partners's 13F filing for Q3 2026, filed 16 Nov 2026.